Viatris Inc is primarily active in the pharmaceutical industry.

The main competitors of Viatris Inc in the market include established pharmaceutical companies such as Pfizer, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Mylan NV, and Novartis AG.

Viatris Inc. is a global pharmaceutical company formed through a merger between Mylan and Upjohn in November 2020. With a rich history, Viatris brings together the experience and expertise of these two renowned organizations. Mylan, founded in 1961, has a legacy of delivering high-quality, affordable medicine to people worldwide. Upjohn, established in 1886, has a long-standing commitment to improving health and well-being. As Viatris Inc., the company continues to build upon this strong foundation, striving to provide innovative treatments, enhance access to healthcare, and improve patient outcomes. With a global presence and a diversified product portfolio, Viatris remains dedicated to addressing unmet medical needs and improving lives.

Viatris Inc, a reputable pharmaceutical company, has achieved several significant milestones. These include the successful merger of Mylan and Upjohn to form Viatris in November 2020. This merger expanded Viatris' global reach and diversified its product portfolio, strengthening its position in the healthcare industry. Furthermore, Viatris has a robust pipeline of innovative generic and biosimilar products, allowing them to provide accessible and affordable healthcare solutions to patients around the world. With its strong commitment to excellence and continuous research and development, Viatris is poised to achieve even greater milestones in the future.

Viatris Inc is primarily present in multiple countries and regions around the world. Some of the key regions where the company has a significant presence include North America, Europe, and Asia-Pacific. This global pharmaceutical company operates in approximately 165 countries, providing a wide range of healthcare products and services. Viatris Inc's diverse geographic footprint allows it to cater to the needs of a diverse customer base and contribute to improving healthcare access and outcomes on a global scale.

Viatris Inc represents a set of core values and a corporate philosophy that guides its operations. The company is committed to delivering access to high-quality medicines worldwide, focusing on enhancing patient experiences and outcomes. Viatris aims to make a difference by providing reliable and affordable healthcare solutions, empowering people to live healthier lives. With a relentless dedication to innovation, integrity, and excellence, Viatris Inc fosters strong partnerships, embraces inclusivity, and prioritizes sustainability. By upholding these values, Viatris strives to positively impact global healthcare and create value for all stakeholders involved.

Analysts currently set an average price target of 13.39 USD for the Viatris stock (median: 13.37 USD), implying -18.5 % versus the latest price. The consensus is based on 18 analyst ratings.

Viatris Analyst Price Targets 2026

18 analysts currently rate the Viatris stock: 11 recommend buying, 5 holding and 2 selling. For 2026, analysts expect Viatris to generate revenue of 14.80 B USD and earnings per share of 2.54 USD.

Viatris Analyst Price Targets 2026

Converted at the current exchange rate, the Viatris share trades at 14.22 EUR (16.43 USD).

The Viatris share (VTRS) is listed on 9 stock exchanges, including: NASDAQ (VTRS), Frankfurt (VIA.F), München (VIA.MU), Düsseldorf (VIA.DU), Hamburg (VIA.HM), London (0A5V.L), Wien (VTRS.VI).

Viatris Inc is a globally operating pharmaceutical and healthcare company focused on the development, manufacturing, and distribution of high-quality generic drugs and biosimilars. The company is headquartered in Pennsylvania, USA and was formed through the merger of Pfizer's global generics division with Mylan in November 2020. Viatris serves patients in over 165 countries and is one of the largest providers of generic drugs and biosimilars worldwide.

The expected revenue of Viatris is 14.80 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Viatris is 2.92 B USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Viatris is currently 6.48. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Viatris stock.

The price-to-sales ratio (P/S) of Viatris is currently 1.28. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Viatris stock.

The Eulerpool Quality Score for Viatris is 1/10.

The ISIN of Viatris is US92556V1061. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Viatris is A2QAME. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Viatris is VTRS. The ticker symbol is used to trade Viatris shares on the stock exchange.

Over the past 12 months, Viatris paid a dividend of 0.48 USD . This corresponds to a dividend yield of about 2.92 %. For the coming 12 months, Viatris is expected to pay a dividend of 0.57 USD.

The current dividend yield of Viatris is 2.92 %.

Viatris pays a dividend, distributed in the months of , , , .

Viatris paid dividends every year for the past 5 years.

For the upcoming 12 months, dividends amounting to 0.57 USD are expected. This corresponds to a dividend yield of 3.48 %.

Viatris is assigned to the 'Health' sector.

To receive the latest dividend of Viatris from amounting to 0.12 USD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Viatris distributed 0.48 USD as dividends.

The dividends of Viatris are distributed in USD.